Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study aims to uncover hidden health risks in 9/11 heroes

NCT ID NCT05216133

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 200 male FDNY rescue workers who were exposed to dust and toxins after the World Trade Center attacks. Many developed acid reflux, which can lead to Barrett's esophagus and even cancer. Researchers will use simple, noninvasive tests like saliva samples and questionnaires to find better ways to detect and understand these conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2023

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Male FDNY rescue and recovery workers between the ages of 37 and 90.

Ages

37 to 90 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 37-90 2. FDNY rescue and recovery worker. 3. Male\* 4. Documented WTC exposure. 5. Consented/Enrolled in the FDNY WTC Health Program 6. Subjects are willing and able to consent for themselves to study enrollment 7. Subjects are willing and able to participate in study procedures 8. Are able to perform their activities of daily living independently 9. Are either light duty or retired FDNY Firefighters 10. Spirometry available within the last 24 months, and at a post-9/11 visit. 11. Have means to accommodate transportation to/from in-person visit Are able to attend a single visit at the CTSI (462 1st Avenue, C \& D 4th Floor) 12. Pre-9/11 spirometry with FEV1%predicted ≥LLN and if not available 1st -post 9/11 spirometry with an FEV1 \>80% predicted. 13. Exposure at the WTC-site within 2 weeks of the 9/11/2001 14. Entered WTC-HP before the site closure on 7/24/2002. 15. Serum from their first post 9/11 WTC-HP visit is available in the FDNY WTC biorepository and may be assayed 16. Are not currently being treated for malignancy 17. Subjects will either need to be defined as having WTC-AHR, WTC-GERD, WTC-BE or be designated controls as per the following additional inclusion criteria are specific to the WTC-aerodigestive disease that the subjects have 18. AHR--A positive methacholine (PC20\<16) and/or positive bronchodilator response (ATS/ERS guidelines: improvement of FEV1 by 12% and at least 200mL) at least once post-9/11.\[95, 96\]No recorded positive AHR testing prior to 9/11 19. GERD Inclusion Criteria * Erosive esophagitis LA grade C or D (as described on endoscopy), OR * Stricture or Barrett's esophagus on endoscopy, OR * Esophageal acid exposure time \>6% on a pH or pH impedance study 19\. BE Inclusion Criteria * Columnar epithelium lining ≥1 cm of the distal esophagus. AND * Histologic examination of biopsy specimens from that columnar epithelium must reveal intestinal metaplasia characterized with goblet cells. Exclusion Criteria: 1. Unwilling to complete an informed consent. 2. Not enrolled in the WTC-HP 3. Do not meet eligibility criteria for AIM 1 or did not have serum available in the biorepository from the first post 9/11 WTC-HP visit. 4. Have pre-existing and documented conditions or concurrent diagnoses, including (and not necessarily limited to) active cancer, severe heart disease, significant cognitive impairment, eating disorders, significant psychiatric illness, end-stage COPD, severe pulmonary hypertension, or organ transplant. 5. High dose steroid (\>20mg prednisone or equivalent) or other hormonal treatments/chemotherapy use in the last month, including testosterone supplementation. 6. Life-expectancy \< 6 months 7. Female\*

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Airway disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • NYU Clinical & Translational Science Institute Clinical Research Center (CTSI CRC)

    New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.